Participated · Series A · Feb 2026

Starget Pharma operates in the United States and Israel and focuses on developing peptide-based radioligand therapies (RLTs) for oncology indications. Its proprietary in-silico, AI-driven discovery platform rapidly identifies and prioritizes radioligand candidates, positioning the company as, in management’s words, the only RLT firm with an AI-powered peptide discovery engine. The lead program is a first-in-class SSTR3-targeted theranostic pair intended for sarcoma, neuroendocrine tumors, and malignant melanoma. A strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) supplies downstream capabilities in imaging, radiochemistry, clinical research, and manufacturing, creating an end-to-end pathway from discovery through early-phase trials. Multiple clinical entries are planned for 2026, supported by newly secured capital to expand U.S. translational and manufacturing infrastructure. Though still pre-revenue, the company’s clinical-stage designation and AI platform aim to generate a repeatable pipeline of RLT programs.

Participated · Series B · Jul 2021

Aleph Farms grows beef steaks from non‑genetically engineered cells isolated from a living cow, producing whole cuts without harming animals. The company released the world’s first cultivated steak in December 2018 and a cultivated ribeye in 2021. Co‑founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg, Aleph Farms is headquartered in Israel. Its global investor network includes L Catterton, DisruptAD (ADQ), BRF, Thai Union and Cargill, and it recently announced an investment from Leonardo DiCaprio, who joined its advisory board. They cite an independent Life Cycle Analysis projecting cultivated beef could reduce climate impact by 92%, air pollution by 93%, use 95% less land and 78% less water versus industrial beef production. Aleph Farms positions its product to deliver familiar meat qualities while eliminating antibiotics and reducing risks of pathogens through an automated, sterile manufacturing process. Aleph Farms grows beef steaks from non-genetically engineered cells isolated from a living cow, producing meat without harming animals and with a reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Technion. Aleph is based in Rehovot, Israel. It raised $105M in a Series B to scale up manufacturing and expand operations internationally ahead of an initial market launch planned for 2022. Near-term milestones include scaling up manufacturing, growing operations internationally, and expanding its product lines and technology platform. The company is working with regulatory agencies on its plans for market entry. Aleph Farms produces real meat cuts grown from cow cells and operates a slaughter-free process to make steaks in large, clean bio-farm facilities similar to dairy operations. Its non-GMO technology, co-developed with Professor Shulamit Levenberg of the Technion, isolates the cells responsible for muscle regeneration and grows them outside the animal to form the same muscle tissue typical of steaks. The company intends to use recent funding to accelerate product development and to transform its prototype into a commercial product. Aleph was co-founded by The Kitchen Hub and Didier Toubia, who serves as CEO. The company is based in Ashdod, Israel and has positioned its platform for scale-up in controlled bio-farm environments.